Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan for Bipolar Depression
NCT04430959Phase 1Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Oct 2020
- Primary completion
- Jul 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of candesartan in bipolar disorder (BD) (2 arms), sponsored by UTHealth Houston. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 4 weeks. Planned start Oct 2020; status: withdrawn.
02
Drugs
candesartan
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT04430959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430959.